Trial watch: Monoclonal antibodies in cancer therapy
E Vacchelli, A Eggermont, J Galon… - …, 2013 - Taylor & Francis
During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …
developed and characterized for their capacity to mediate antineoplastic effects, either as …
[HTML][HTML] Trial watch: Monoclonal antibodies in cancer therapy
E Vacchelli, A Eggermont, J Galon… - …, 2013 - ncbi.nlm.nih.gov
During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …
developed and characterized for their capacity to mediate antineoplastic effects, either as …
[PDF][PDF] Trial watch
G Kroemer, L Galluzzi - scienceopen.com
In 1975, Georges Köhler and César Milstein described for the first time an experimental
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
[PDF][PDF] Trial watch
G Kroemer, L Galluzzi - 2013 - academia.edu
In 1975, Georges Köhler and César Milstein described for the first time an experimental
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
[PDF][PDF] Trial watch
G Kroemer, L Galluzzi - Citeseer
In 1975, Georges Köhler and César Milstein described for the first time an experimental
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
setup allowing for the cost-effective production of high quantities of antibodies exhibiting the …
Trial watch: Monoclonal antibodies in cancer therapy
E Vacchelli, A Eggermont, J Galon… - …, 2013 - pubmed.ncbi.nlm.nih.gov
During the past 20 years, dozens-if not hundreds-of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …
developed and characterized for their capacity to mediate antineoplastic effects, either as …
Trial watch: Monoclonal antibodies in cancer therapy.
E Vacchelli, A Eggermont, J Galon… - …, 2013 - europepmc.org
During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …
developed and characterized for their capacity to mediate antineoplastic effects, either as …
Trial watch: Monoclonal antibodies in cancer therapy.
E Vacchelli, A Eggermont, J Galon… - …, 2013 - europepmc.org
During the past 20 years, dozens—if not hundreds—of monoclonal antibodies have been
developed and characterized for their capacity to mediate antineoplastic effects, either as …
developed and characterized for their capacity to mediate antineoplastic effects, either as …